IL160918A0 - Himbacine analogues as thrombin receptor antagonists - Google Patents

Himbacine analogues as thrombin receptor antagonists

Info

Publication number: IL160918A0
Authority: IL; Israel
Prior art keywords: himbacine; analogues; receptor antagonists; thrombin receptor; thrombin
Prior art date: 2001-10-18

Application number

IL16091802A

Other languages

English (en)

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-18

Filing date

2002-10-16

Publication date

2004-08-31

2002-10-16 Application filed by Schering Corp filed Critical Schering Corp

2004-08-31 Publication of IL160918A0 publication Critical patent/IL160918A0/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

IL16091802A 2001-10-18 2002-10-16 Himbacine analogues as thrombin receptor antagonists IL160918A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33035901P	2001-10-18	2001-10-18
PCT/US2002/032936 WO2003033501A1 (en)	2001-10-18	2002-10-16	Himbacine analogues as thrombin receptor antagonists

Publications (1)

Publication Number	Publication Date
IL160918A0 true IL160918A0 (en)	2004-08-31

Family

ID=23289411

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16091802A IL160918A0 (en)	2001-10-18	2002-10-16	Himbacine analogues as thrombin receptor antagonists

Country Status (23)

Country	Link
US (2)	US7037920B2 (xx)
EP (1)	EP1436298B1 (xx)
JP (2)	JP4307260B2 (xx)
KR (1)	KR100960170B1 (xx)
CN (1)	CN100369917C (xx)
AR (1)	AR036832A1 (xx)
AT (1)	ATE525378T1 (xx)
AU (1)	AU2002335031C1 (xx)
BR (1)	BR0213967A (xx)
CA (1)	CA2463628A1 (xx)
CO (1)	CO5570668A2 (xx)
EC (1)	ECSP045064A (xx)
HU (1)	HUP0500443A3 (xx)
IL (1)	IL160918A0 (xx)
MX (1)	MXPA04003610A (xx)
MY (1)	MY139335A (xx)
NO (1)	NO329349B1 (xx)
NZ (1)	NZ531869A (xx)
PE (1)	PE20030808A1 (xx)
PL (1)	PL371948A1 (xx)
RU (1)	RU2319704C9 (xx)
WO (1)	WO2003033501A1 (xx)
ZA (1)	ZA200402849B (xx)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6346510B1 (en)	1995-10-23	2002-02-12	The Children's Medical Center Corporation	Therapeutic antiangiogenic endostatin compositions
US7235567B2 (en) *	2000-06-15	2007-06-26	Schering Corporation	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7488742B2 (en) *	2000-06-15	2009-02-10	Schering Corporation	Thrombin receptor antagonists
ATE378330T1 (de)	2002-04-16	2007-11-15	Schering Corp	Trizyklische thrombin rezeptor antagonisten
WO2005007868A2 (en) *	2003-07-08	2005-01-27	Accumetrics, Inc.	Controlled platelet activation to monitor therapy of adp antagonists
US20070243632A1 (en) *	2003-07-08	2007-10-18	Coller Barry S	Methods for measuring platelet reactivity of patients that have received drug eluting stents
ATE406366T1 (de) *	2004-05-28	2008-09-15	Schering Corp	Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
EP1778652A2 (en) *	2004-08-20	2007-05-02	EntreMed, Inc.	Compositions and methods comprising proteinase activated receptor antagonists
CA2582353A1 (en) *	2004-10-06	2006-04-20	University Of Rochester	Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
WO2006041872A2 (en) *	2004-10-08	2006-04-20	Schering Corporation	Thrombin receptor antagonists
PL2206697T3 (pl)	2005-01-14	2012-03-30	Merck Sharp & Dohme	Egzo- oraz diastereoselektywna synteza analogów himbacyny
US7772276B2 (en) *	2005-01-14	2010-08-10	Schering Corporation	Exo-selective synthesis of himbacine analogs
WO2006076564A1 (en) *	2005-01-14	2006-07-20	Schering Corporation	Synthesis of himbacine analogs
KR20070116066A (ko) *	2005-03-31	2007-12-06	쉐링 코포레이션	스피로사이클릭 트롬빈 수용체 길항제
US7595169B2 (en) *	2005-04-27	2009-09-29	Accumetrics, Inc.	Method for determining percent platelet aggregation
WO2007075808A2 (en) *	2005-12-20	2007-07-05	Schering Corporation	Methods for preventing and/or treating a cell proliferative disorder
CN101384590A (zh) *	2005-12-22	2009-03-11	先灵公司	作为凝血酶受体拮抗剂的唑并异喹啉
EP1971336A2 (en) *	2005-12-22	2008-09-24	Shering Corporation	Thrombin receptor antagonists as phophylaxis to complications from cardiopulmonary surgery
KR20080104352A (ko) *	2006-03-29	2008-12-02	쉐링 코포레이션	트롬빈 수용체 길항제로서 유용한 모노사이클릭 및 비사이클릭 힘바신 유도체
EP2266976B1 (en)	2006-04-13	2013-07-31	Merck Sharp & Dohme Corp.	Fused ring thrombin receptor antagonists
AR061664A1 (es) *	2006-06-29	2008-09-10	Schering Corp	Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas.
AR061727A1 (es)	2006-06-30	2008-09-17	Schering Corp	Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI367112B (en) *	2006-06-30	2012-07-01	Schering Corp	Immediate-release tablet formulations of a thrombin receptor antagonist
TWI343262B (en) *	2006-09-26	2011-06-11	Schering Corp	Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
WO2008060372A2 (en) *	2006-10-04	2008-05-22	Schering Corporation	Thrombin receptor antagonists based on the modified tricyclic unit of himbacine
US8153664B2 (en) *	2006-10-04	2012-04-10	Schering Corporation	Bicyclic and tricyclic derivatives as thrombin receptor antagonists
WO2008079260A2 (en) *	2006-12-22	2008-07-03	Schering Corporation	Disintegration promoters in solid dose wet granulation formulations
JP2010522169A (ja) *	2007-03-23	2010-07-01	シェーリングコーポレイション	トロンビン受容体アンタゴニストの使用による、経皮的インターベンション後の有害事象の低減
KR20100017576A (ko) *	2007-05-03	2010-02-16	아큐메트릭스, 인크.	트롬빈 수용체 길항제에 의한 혈소판 응집 억제의 측정 방법
MY152040A (en)	2008-02-05	2014-08-15	Sanofi Aventis	Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
EP2300435A2 (en)	2008-05-19	2011-03-30	Schering Corporation	Heterocyclic compounds as factor ixa inhibitors
WO2010141525A1 (en)	2009-06-04	2010-12-09	Schering Corporation	Active metabolite of a thrombin receptor antagonist
EP2440191A2 (en)	2009-06-08	2012-04-18	Schering Corporation	A thrombin receptor antagonist and clopidogrel fixed dose tablet
WO2011017296A1 (en)	2009-08-04	2011-02-10	Schering Corporation	4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
US9340530B2 (en)	2012-03-06	2016-05-17	Merck Sharp & Dohme Corp.	Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
EP3035928B1 (en)	2013-08-22	2023-10-18	Merck Sharp & Dohme LLC	3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
WO2015026693A1 (en)	2013-08-22	2015-02-26	Merck Sharp & Dohme Corp.	7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
EP3035930A4 (en)	2013-08-22	2017-03-08	Merck Sharp & Dohme Corp.	7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
US9969724B2 (en)	2014-04-16	2018-05-15	Merck Sharp & Dohme Corp.	Factor IXa inhibitors
CN104610330A (zh) *	2015-02-25	2015-05-13	成都安斯利生物医药有限公司	一种制备(e)-3-丙烯酸乙酯频呐硼酸酯的方法
JP2023534704A (ja)	2020-07-22	2023-08-10	ヤンセンファーマシューティカエヌ．ベー．	第ｘｉａ因子阻害剤として有用な化合物
US11814364B2 (en)	2021-03-18	2023-11-14	Janssen Pharmaceutica Nv	Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en)	2021-03-18	2023-12-19	Janssen Pharmaceutica Nv	Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en)	2021-03-18	2024-03-05	Janssen Pharmaceutica Nv	Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11897880B2 (en)	2021-04-30	2024-02-13	Janssen Pharmaceutica Nv	7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en)	2021-07-22	2024-04-16	Janssen Pharmaceutica Nv	Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5716952A (en)	1992-03-18	1998-02-10	Allergan	Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
IL106197A (en)	1992-07-30	1999-11-30	Cor Therapeutics Inc	Agagonists for the rhombin receptors and pharmaceutical preparations containing them
JP2000229961A (ja) *	1998-12-11	2000-08-22	Sagami Chem Res Center	ヒドロナフト［２，３−ｃ］フラン誘導体およびその製造方法
US6063847A (en) *	1997-11-25	2000-05-16	Schering Corporation	Thrombin receptor antagonists
DE19801636A1 (de) *	1998-01-17	1999-07-22	Bayer Ag	Substituierte bicyclische Lactone
CA2410177C (en)	2000-06-15	2010-05-11	Schering Corporation	Thrombin receptor antagonists

2002
- 2002-10-16 MX MXPA04003610A patent/MXPA04003610A/es active IP Right Grant
- 2002-10-16 MY MYPI20023859A patent/MY139335A/en unknown
- 2002-10-16 KR KR1020047005435A patent/KR100960170B1/ko not_active IP Right Cessation
- 2002-10-16 CA CA002463628A patent/CA2463628A1/en not_active Abandoned
- 2002-10-16 PE PE2002001022A patent/PE20030808A1/es not_active Application Discontinuation
- 2002-10-16 US US10/271,715 patent/US7037920B2/en not_active Expired - Fee Related
- 2002-10-16 AR ARP020103876A patent/AR036832A1/es unknown
- 2002-10-16 EP EP02801732A patent/EP1436298B1/en not_active Expired - Lifetime
- 2002-10-16 AU AU2002335031A patent/AU2002335031C1/en not_active Ceased
- 2002-10-16 JP JP2003536240A patent/JP4307260B2/ja not_active Expired - Fee Related
- 2002-10-16 WO PCT/US2002/032936 patent/WO2003033501A1/en active IP Right Grant
- 2002-10-16 BR BR0213967-7A patent/BR0213967A/pt not_active IP Right Cessation
- 2002-10-16 AT AT02801732T patent/ATE525378T1/de not_active IP Right Cessation
- 2002-10-16 NZ NZ531869A patent/NZ531869A/en not_active IP Right Cessation
- 2002-10-16 IL IL16091802A patent/IL160918A0/xx not_active IP Right Cessation
- 2002-10-16 HU HU0500443A patent/HUP0500443A3/hu unknown
- 2002-10-16 RU RU2004115114/04A patent/RU2319704C9/ru not_active IP Right Cessation
- 2002-10-16 CN CNB028206665A patent/CN100369917C/zh not_active Expired - Fee Related
- 2002-10-16 PL PL02371948A patent/PL371948A1/xx not_active Application Discontinuation
2004
- 2004-04-15 EC EC2004005064A patent/ECSP045064A/es unknown
- 2004-04-15 ZA ZA200402849A patent/ZA200402849B/xx unknown
- 2004-04-16 CO CO04034781A patent/CO5570668A2/es not_active Application Discontinuation
- 2004-05-14 NO NO20042021A patent/NO329349B1/no not_active IP Right Cessation
2005
- 2005-12-19 US US11/311,083 patent/US20060106050A1/en not_active Abandoned
2008
- 2008-09-17 JP JP2008238716A patent/JP2009029820A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CN100369917C (zh)	2008-02-20
NZ531869A (en)	2006-11-30
HUP0500443A2 (hu)	2005-08-29
RU2319704C2 (ru)	2008-03-20
CN1571789A (zh)	2005-01-26
US7037920B2 (en)	2006-05-02
MY139335A (en)	2009-09-30
EP1436298A1 (en)	2004-07-14
NO20042021L (no)	2004-05-14
KR100960170B1 (ko)	2010-05-26
PL371948A1 (en)	2005-07-11
HUP0500443A3 (en)	2009-12-28
CO5570668A2 (es)	2005-10-31
PE20030808A1 (es)	2003-09-22
AR036832A1 (es)	2004-10-06
JP2005529841A (ja)	2005-10-06
US20060106050A1 (en)	2006-05-18
MXPA04003610A (es)	2004-07-27
NO329349B1 (no)	2010-10-04
CA2463628A1 (en)	2003-04-24
JP2009029820A (ja)	2009-02-12
AU2002335031C1 (en)	2006-11-16
AU2002335031B2 (en)	2005-06-30
RU2004115114A (ru)	2005-10-27
ATE525378T1 (de)	2011-10-15
BR0213967A (pt)	2005-08-30
JP4307260B2 (ja)	2009-08-05
US20030203927A1 (en)	2003-10-30
ECSP045064A (es)	2004-05-28
WO2003033501A1 (en)	2003-04-24
EP1436298B1 (en)	2011-09-21
RU2319704C9 (ru)	2008-08-20
ZA200402849B (en)	2005-01-14
KR20050036845A (ko)	2005-04-20

Legal Events

Date	Code	Title	Description
2012-03-29	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
IL160918A0 (en)	2004-08-31	Himbacine analogues as thrombin receptor antagonists
AU6690001A (en)	2001-12-24	Thrombin receptor antagonists
IL174538A0 (en)	2006-08-01	Thrombin receptor antagonists
IL165841A0 (en)	2006-01-15	Mchir antagonists
AU2002367424A1 (en)	2003-07-24	Androgen receptor antagonists
HK1083188A1 (en)	2006-06-30	Diaryl ethers as opioid receptor antagonists
AU2003241836A1 (en)	2004-04-23	Lpa receptor antagonists
AU2003261392A8 (en)	2004-02-23	M3muscarinic acetylcholine receptor antagonists
EP1444251A4 (en)	2005-12-21	CYCLIC PEPTIDES AS G PROTEIN-COUPLED RECEPTOR ANTAGONISTS
EP1351933A4 (en)	2005-09-07	ANTAGONISTS OF IL-8 RECEPTORS
AU2003251739A8 (en)	2004-01-23	New neuropeptide y y5 receptor antagonists
GB0130261D0 (en)	2002-02-06	Lactams as tachykinin antagonists
HK1066787A1 (en)	2005-04-01	Nk1 antagonists nk1
HK1063791A1 (en)	2005-01-14	Nk1 antagonists
PL370799A1 (en)	2005-05-30	Aminotetralin derivatives as muscarinic receptor antagonists
IL144299A0 (en)	2002-05-23	N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
PL362838A1 (en)	2004-11-02	Somatostatin antagonists
IL157713A0 (en)	2004-03-28	Aryl oxime-piperazines useful as ccr5 antagonists
AU2003297773A8 (en)	2004-07-29	Heteroaryl peptidomimetics as thrombin receptor antagonists
AU2002359524A8 (en)	2003-06-17	P2x7 receptor antagonists
PL370821A1 (en)	2005-05-30	N-ureido-piperidines as antagonists viii for ccr-3 receptor
PL370367A1 (en)	2005-05-16	Ccr-3 receptor antagonists v
GB0101223D0 (en)	2001-02-28	Histamine receptor antagonists
EP1551401A4 (en)	2006-03-22	MANNITOL FORMULATION FOR AN INTEGRIN RECEPTOR ANTAGONIST
GB0026327D0 (en)	2000-12-13	Thrombin receptor antagonists